Advertisement
AGIO vs MCRB
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AGIO is a Buy and MCRB is a Buy.
AGIO in upward trend: 10-day moving average moved above 50-day moving average on October 23, 2026
The 10-day moving average for AGIO crossed bullishly above the 50-day moving average on October 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 19 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for AGIO just turned positive on October 19, 2026. Looking at past instances where AGIO's MACD turned positive, the stock continued to rise in 39 of 50 cases over the following month. The odds of a continued upward trend are 78%.
Following a +3.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where AGIO advanced for three days, in 229 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Bearish Trend Analysis
The 10-day RSI Indicator for AGIO moved out of overbought territory on October 29, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 26 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 79%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 52 of 67 cases where AGIO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 78%.
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AGIO as a result. In 77 of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.
AGIO moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AGIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
AGIO broke above its upper Bollinger Band on October 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AGIO entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.778) is normal, around the industry mean (3.162). P/E Ratio (-4.358) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (19.685) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. AGIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AGIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
MCRB's Indicator enters downward trend
The Aroon Indicator for MCRB entered a downward trend on October 30, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 265 similar instances where the Aroon Indicator formed such a pattern. In 239 of the 265 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MCRB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for MCRB just turned positive on October 29, 2026. Looking at past instances where MCRB's MACD turned positive, the stock continued to rise in 37 of 41 cases over the following month. The odds of a continued upward trend are 90%.
MCRB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.515) is normal, around the industry mean (3.162). P/E Ratio (-0.731) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (21.008) is also within normal values, averaging (439.647).
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. MCRB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MCRB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
AGIO | MCRB | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 26 Undervalued | 42 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 98 | |
PRICE GROWTH RATING 1..100 | 59 | 96 | |
P/E GROWTH RATING 1..100 | 99 | 97 | |
SEASONALITY SCORE 1..100 | 75 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AGIO's Valuation (26) in the Biotechnology industry is in the same range as MCRB (42). This means that AGIO’s stock grew similarly to MCRB’s over the last 12 months.
AGIO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as MCRB (100). This means that AGIO’s stock grew similarly to MCRB’s over the last 12 months.
AGIO's SMR Rating (97) in the Biotechnology industry is in the same range as MCRB (98). This means that AGIO’s stock grew similarly to MCRB’s over the last 12 months.
AGIO's Price Growth Rating (59) in the Biotechnology industry is somewhat better than the same rating for MCRB (96). This means that AGIO’s stock grew somewhat faster than MCRB’s over the last 12 months.
MCRB's P/E Growth Rating (97) in the Biotechnology industry is in the same range as AGIO (99). This means that MCRB’s stock grew similarly to AGIO’s over the last 12 months.
| AGIO | MCRB | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 79% | N/A |
| Stochastic ODDS (%) | 2 days ago 78% | N/A |
| Momentum ODDS (%) | 2 days ago 75% | N/A |
| MACD ODDS (%) | 2 days ago 78% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 75% | 2 days ago 89% |
| TrendMonth ODDS (%) | 2 days ago 74% | 2 days ago 90% |
| Advances ODDS (%) | 4 days ago 77% | N/A |
| Declines ODDS (%) | 2 days ago 75% | 4 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 79% | 2 days ago 85% |
| Aroon ODDS (%) | 2 days ago 75% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AGIO’s FA Score shows that 1 FA rating(s) are green while MCRB’s FA Score has 0 green FA rating(s).
- AGIO’s FA Score: 1 green, 4 red.
- MCRB’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AGIO’s TA Score shows that 3 TA indicator(s) are bullish while MCRB’s TA Score has 2 bullish TA indicator(s).
- AGIO’s TA Score: 3 bullish, 7 bearish.
- MCRB’s TA Score: 2 bullish, 2 bearish.
Price Growth
AGIO (@Biotechnology) experienced а -17.43% price change this week, while MCRB (@Biotechnology) price change was -15.31% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.20%. For the same industry, the average monthly price growth was -14.01%, and the average quarterly price growth was -15.33%.
Reported Earning Dates
AGIO is expected to report earnings on Nov 05, 2026.
MCRB is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Biotechnology (+0.20% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
MCRB and
Correlation & Price change
A.I.dvisor indicates that over the last year, MCRB has been loosely correlated with ORMP. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if MCRB jumps, then ORMP could also see price increases.
| Ticker / NAME | Correlation To MCRB | 1D Price Change % | ||
|---|---|---|---|---|
| MCRB | 100% | -9.23% | ||
| ORMP - MCRB | 42% Loosely correlated | -2.84% | ||
| AXON - MCRB | 38% Loosely correlated | -2.35% | ||
| AMRN - MCRB | 36% Loosely correlated | -4.91% | ||
| ARRY - MCRB | 34% Loosely correlated | -4.78% | ||
| TAOX - MCRB | 34% Loosely correlated | -10.44% | ||
More | ||||